+ 1.73
+ 0.5%
+ 5.77
+ 1.73%
+ 5.82
+ 1.4%
+ 2.00
+ 1.21%

Panaxia And Neuraxpharm Advance Partnership To Bring Medical Cannabis To France

November 23, 2020 10:10 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Panaxia And Neuraxpharm Advance Partnership To Bring Medical Cannabis To France

Israel medical cannabis producer Panaxia Labs Israel (TASE: PNAX) and European pharmaceutical company Neuraxpharm are planning to reach the French market.

The two companies have agreed to a production, marketing, and delivery partnership to distribute Panaxia’s medical cannabis products across France.

The new deal is similar to the one the companies made for Germany. This means Panaxia will be in charge of the product production, while Neuraxpharm will take over commercialization, branding, delivery, and sales.

Per the arrangement, the companies will first propose a joint response to the tender issued by the French government and the French National Agency for Medicines and Health Products Safety (ANSM) for a pilot to organize the medical cannabis industry in France.

It is projected for the pilot to start in the upcoming months and last for around two years, during which few companies will be chosen to deliver its medical cannabis products for free to 3,000 patients who fall under specified criteria.

Once the pilot is completed, it will be up to the French government to make a final call on the further use and sale of medical cannabis products in the country.

If the French government says yes to the cannabis medical industry, Panaxia plans to apply for regulatory authorization for the commercialization and distribution of the products in France. Panaxia reminded it the only Israeli company EU-GMP certified by a European agency for manufacture and export of medical cannabis.

"We are delighted to expand our strategic collaboration with Panaxia,” Neuraxpharm CEO Jörg-Thomas Dierks said. “As part of our commitment to finding new solutions to respond to the needs of patients, we are very excited to be pioneers in the emerging medical cannabis sector in France and to expand our CNS product portfolio for our patients. We believe that in the coming years, France will also join the accelerated trend in Europe and embrace the use of medical cannabis for patients who meet the criteria for the various indications."

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Cannabis News Markets

Related Articles

High Tide Stock Could See A Breakout In The Coming Weeks: Here's Why

High Tide Inc (NASDAQ: HITI) shares climbed higher Friday on continued momentum after the company announced Thursday it would release its financial and operational results for Q2 of 2021 after market close on June 28, 2021. read more

Why Cannabis-Specific Cryptos Will Not Take On Mainstream, But Crypto In Cannabis Might

Since the eruption of altcoins, the crypto space has experienced a wide variety of wonders and unexpected events. Smart contracts, Lighting network, DeFi, scams, bubbles and failed projects to name some of the most obvious. In the midst of this frenzy, a fascinating concept appeared: Cannabis Crypto.  read more

Technology, Social Equity, And The Cannabis Industry

This article by Tiffani Wroe was originally published on Cannabis & Tech Today, and appears here with permission. There are dozens of good reasons for legalizing cannabis, and one of the most compelling is its potential for social justice. read more

EXCLUSIVE: Jordan Tishler, MD Talks About Medical Cannabis, Success Rates, Side Effects And That It Should Be A Specialty Field Of Its Own

While the Internet appears to have all the answers we need, it is more important than ever to know how to use it, where to look for information, and more importantly, to confirm if it is indeed true. Mark Twain is attributed as saying: "A lie can travel halfway around the world before the truth puts on its shoes.” read more